Investigational drug · Phase 3
SHR-1703
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Eosinophilic Granulomatosis With Polyangiitis, Eosinophilic Asthma Patients.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
8
Any phase or sponsor naming "SHR-1703"
First trial start
2023
Nov 16, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-1703", any sponsor or status.
Conditions studied
As listed on its trial records.
- Eosinophilic Granulomatosis With Polyangiitis
- Eosinophilic Asthma Patients
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-1703" as an intervention, largest first.
- A Multi-centered,Randomized,Double-blind,Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic AsthmaPivotal-lookingActive, not recruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT06653322 · 401 participants · Start Nov 21, 2024 · Primary completion Sep 2027
Drug: HR-1703; Placebo · For: Asthma With Eosinophilic Phenotype
Sites: Chengdu, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT06441812 · 200 participants (planned) · Start Jul 19, 2024 · Primary completion Sep 2028
Drug: SHR-1703 Injection · For: Eosinophilic Asthma Patients
Sites: Chengdu, China
- A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis (EGPA)Pivotal-lookingRecruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT05979051 · 166 participants (planned) · Start Nov 16, 2023 · Primary completion Dec 2028
Drug: SHR-1703; Mepolizumab Injection · For: Eosinophilic Granulomatosis With Polyangiitis
Sites: Beijing, China; Hangzhou, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05522439 · 85 participants · Start Dec 22, 2022 · Primary completion Sep 12, 2024
Drug: SHR-1703; SHR-1703 Placebo · For: Asthma With Eosinophilic Phenotype
Sites: Chengdu, China
- A Study Comparing a Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy ParticipantsNot yet recruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07701239 · 84 participants (planned) · Start Jul 2026 · Primary completion Apr 2027
Drug: SHR-1703 Injection; SHR-1703 Injection · For: Asthma With Eosinophilic Phenotype
Sites: Hangzhou, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04480762 · 42 participants · Start Aug 4, 2020 · Primary completion Sep 21, 2021
Drug: SHR-1703; Placebo · For: Asthma
Sites: Chengdu, China
- A Trial of SHR-1703 in AsthmaStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05042401 · 23 participants · Start Oct 12, 2021 · Primary completion Jun 15, 2023
Drug: SHR-1703; placebo and 2 more · For: Asthma
Sites: Chengdu, China
- A Trial of SHR-1703 in Healthy SubjectsTerminated
Atridia Pty Ltd.Industry
NCT04855591 · 1 participants · Start Jun 14, 2021 · Primary completion Sep 13, 2021
Drug: SHR-1703; Placebo · For: Asthma
Sites: Brisbane, Australia
Newest research
PubMed records naming it or its code names, newest first.
- SHR-1703, a novel long-acting anti-interleukin-5 monoclonal antibody, in asthma patients: A randomized, double-blind, placebo-controlled phase 1 study.
Yang L, He L, Zhang Y, et al. · Br J Clin Pharmacol 2026
- Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study.
Yang L, Fang Y, Luo Y, et al. · Expert Opin Investig Drugs 2024
Also in development for Eosinophilic Granulomatosis With Polyangiitis
- NS-229Phase 21 trial
NS Pharma, Inc. · Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.